Achieve Life Sciences, Inc. (ACHV) News
Filter ACHV News Items
ACHV News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ACHV News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ACHV News From Around the Web
Below are the latest news stories about ACHIEVE LIFE SCIENCES INC that investors may wish to consider to help them evaluate ACHV as an investment opportunity.
Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of DirectorsNew Directors Bring Extensive Leadership Experience in Corporate Strategy and CommercializationSEATTLE and VANCOUVER, British Columbia, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Kristen Slaoui, Ph.D., and Nancy Phelan will join its Board of Directors. Achieve also announced that current |
Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA SubmissionOver 300 Participants Have Completed Cumulative Six Months of Cytisinicline Treatment in the ORCA-OL Trial, Completing the Long-Term Exposure Requirement for NDA Submission ORCA-OL Long-Term Exposure Timelines Remain on Track with No Safety Concerns Identified Planned Cytisinicline NDA Submission on Target for Q2 2025 SEATTLE and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the global dev |
Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference WeekSEATTLE and VANCOUVER, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the development and commercialization of cytisinicline for nicotine dependence, announced today that the company will be hosting in-person one-on-one meetings coinciding with the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, January 13-16, 2025. Rick Stewart, Chief Executive Officer of Achieve, along with other mem |
Should You Expect a Strong Re-rating for Achieve Life Sciences (ACHV) Post Results in Q1?Rogue Funds, an investment management company, released its third quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund returned -3.03% net of fees in the quarter. The fund faced a slight decline in the value of the portfolio, which was quite disappointing. Two of the fund’s core positions fell […] |
Institutional shareholders may be less affected by Achieve Life Sciences, Inc.'s (NASDAQ:ACHV) pullback last week after a year of 0.5% returnsKey Insights Given the large stake in the stock by institutions, Achieve Life Sciences' stock price might be vulnerable... |
Achieve Life Sciences Appoints Mark Oki as Chief Financial OfficerSEATTLE and VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, today announced that Mark Oki has joined the company as its Chief Financial Officer, effective December 5, 2024. Mr. Oki will oversee the company's financial strategy and operations, including accounting, investor relations, inf |
Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDAMilestone Reinforces the Potential for Cytisinicline as a First-in-Class Treatment for Vaping CessationSEATTLE and VANCOUVER, British Columbia, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company focused on the development and commercialization of cytisinicline for nicotine dependence, announced today the successful outcome of its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). This meeting represents a key mi |
Achieve Life Sciences Announces Participation at Upcoming Investor ConferencesSEATTLE and VANCOUVER, British Columbia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, today announced that Rick Stewart, CEO of Achieve Life Sciences, and management will be participating at two upcoming investor conferences. Meetings will be conducted at the Jefferies London Healthcare Conference on November 19- |
ACHV: Commercialization in FocusBy John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT 3Q:24 Operational and Financial Results Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported third quarter 2024 results in a November 7th press release distributed after the market's close. The company subsequently held a conference call discussing progress with the ORCA OL trial, pre-commercialization activities and the |
Achieve Life Sciences Inc (ACHV) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...Achieve Life Sciences Inc (ACHV) secures FDA breakthrough designation and completes key trial enrollment, while navigating financial and operational hurdles. |